| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Care Costs | 55 | 2024 | 3240 | 3.840 |
Why?
|
| Hemoglobinuria, Paroxysmal | 5 | 2023 | 95 | 2.760 |
Why?
|
| Medication Adherence | 17 | 2024 | 2166 | 2.450 |
Why?
|
| Cost of Illness | 21 | 2024 | 1931 | 2.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 17 | 2024 | 3202 | 2.190 |
Why?
|
| Adrenal Cortex Hormones | 20 | 2024 | 1874 | 1.940 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 31 | 2024 | 11729 | 1.760 |
Why?
|
| Bronchodilator Agents | 9 | 2024 | 512 | 1.700 |
Why?
|
| Erythropoietin | 13 | 2009 | 719 | 1.670 |
Why?
|
| Neurofibroma, Plexiform | 2 | 2024 | 66 | 1.670 |
Why?
|
| Retrospective Studies | 178 | 2024 | 80430 | 1.670 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 9 | 2024 | 111 | 1.480 |
Why?
|
| Managed Care Programs | 9 | 2014 | 940 | 1.420 |
Why?
|
| Hospitalization | 28 | 2024 | 10698 | 1.410 |
Why?
|
| Health Resources | 13 | 2024 | 935 | 1.400 |
Why?
|
| Anti-Asthmatic Agents | 9 | 2024 | 571 | 1.330 |
Why?
|
| Anemia | 15 | 2009 | 1508 | 1.300 |
Why?
|
| Administration, Inhalation | 15 | 2024 | 1156 | 1.290 |
Why?
|
| Absenteeism | 5 | 2020 | 247 | 1.290 |
Why?
|
| Muscarinic Antagonists | 6 | 2024 | 135 | 1.240 |
Why?
|
| Chlorobenzenes | 6 | 2022 | 28 | 1.210 |
Why?
|
| Neurofibromatosis 1 | 2 | 2024 | 560 | 1.200 |
Why?
|
| Phenylurea Compounds | 6 | 2021 | 528 | 1.190 |
Why?
|
| Anticonvulsants | 14 | 2021 | 1903 | 1.180 |
Why?
|
| Insurance Claim Review | 17 | 2024 | 735 | 1.150 |
Why?
|
| Asthma | 17 | 2024 | 6195 | 1.120 |
Why?
|
| Cardiac Resynchronization Therapy | 3 | 2022 | 553 | 1.110 |
Why?
|
| United States | 100 | 2024 | 72202 | 1.090 |
Why?
|
| Trifluridine | 3 | 2021 | 28 | 1.020 |
Why?
|
| Multiple Myeloma | 9 | 2024 | 5143 | 0.990 |
Why?
|
| Chelation Therapy | 5 | 2018 | 77 | 0.980 |
Why?
|
| Kidney Neoplasms | 15 | 2023 | 4241 | 0.970 |
Why?
|
| Melanoma | 6 | 2019 | 5704 | 0.960 |
Why?
|
| Herpes Zoster | 4 | 2024 | 253 | 0.950 |
Why?
|
| Patient Acceptance of Health Care | 15 | 2024 | 3190 | 0.940 |
Why?
|
| Middle Aged | 151 | 2024 | 220382 | 0.940 |
Why?
|
| Epilepsy | 12 | 2021 | 3286 | 0.930 |
Why?
|
| Pyrroles | 5 | 2022 | 1126 | 0.910 |
Why?
|
| Imidazoles | 6 | 2018 | 1179 | 0.900 |
Why?
|
| Aged | 126 | 2024 | 168840 | 0.900 |
Why?
|
| Longitudinal Studies | 36 | 2024 | 14565 | 0.890 |
Why?
|
| Drugs, Generic | 7 | 2010 | 447 | 0.880 |
Why?
|
| Male | 180 | 2024 | 360035 | 0.880 |
Why?
|
| Drug Combinations | 13 | 2024 | 2043 | 0.840 |
Why?
|
| Antipsychotic Agents | 10 | 2017 | 3066 | 0.840 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2021 | 112 | 0.840 |
Why?
|
| Carcinoma, Renal Cell | 10 | 2023 | 3159 | 0.830 |
Why?
|
| Female | 177 | 2024 | 391875 | 0.810 |
Why?
|
| Humans | 260 | 2024 | 760437 | 0.810 |
Why?
|
| Iron Chelating Agents | 5 | 2019 | 141 | 0.810 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2021 | 24 | 0.800 |
Why?
|
| Rotavirus Infections | 3 | 2017 | 84 | 0.780 |
Why?
|
| Adult | 125 | 2024 | 220781 | 0.780 |
Why?
|
| Insurance, Disability | 2 | 2019 | 27 | 0.780 |
Why?
|
| Indoles | 4 | 2014 | 1833 | 0.770 |
Why?
|
| Thymine | 3 | 2021 | 68 | 0.760 |
Why?
|
| Medicaid | 14 | 2020 | 2810 | 0.760 |
Why?
|
| Disease Progression | 12 | 2024 | 13484 | 0.750 |
Why?
|
| Drug Costs | 11 | 2010 | 1179 | 0.740 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2014 | 2047 | 0.730 |
Why?
|
| Industry | 2 | 2020 | 364 | 0.730 |
Why?
|
| Hematinics | 7 | 2009 | 282 | 0.720 |
Why?
|
| Prostatic Hyperplasia | 2 | 2021 | 521 | 0.690 |
Why?
|
| Databases, Factual | 21 | 2022 | 7948 | 0.690 |
Why?
|
| Hypoglycemic Agents | 8 | 2018 | 3076 | 0.680 |
Why?
|
| Diphosphonates | 3 | 2010 | 636 | 0.660 |
Why?
|
| Insurance, Health | 15 | 2021 | 2491 | 0.660 |
Why?
|
| Pyrrolidines | 3 | 2021 | 338 | 0.660 |
Why?
|
| Administration, Oral | 14 | 2024 | 4010 | 0.650 |
Why?
|
| Weight Loss | 5 | 2018 | 2683 | 0.640 |
Why?
|
| Anemia, Sickle Cell | 4 | 2015 | 1063 | 0.630 |
Why?
|
| Malignant Carcinoid Syndrome | 5 | 2019 | 30 | 0.630 |
Why?
|
| Candidiasis, Invasive | 1 | 2018 | 23 | 0.630 |
Why?
|
| Echinocandins | 1 | 2018 | 52 | 0.620 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2021 | 344 | 0.620 |
Why?
|
| Benzyl Alcohols | 6 | 2022 | 30 | 0.600 |
Why?
|
| Anemia, Aplastic | 1 | 2020 | 228 | 0.600 |
Why?
|
| Cohort Studies | 49 | 2024 | 41366 | 0.580 |
Why?
|
| Blood Transfusion | 9 | 2020 | 1299 | 0.580 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2024 | 1640 | 0.580 |
Why?
|
| Pyridines | 5 | 2021 | 2868 | 0.580 |
Why?
|
| Nebulizers and Vaporizers | 4 | 2022 | 138 | 0.580 |
Why?
|
| Health Services | 5 | 2017 | 752 | 0.560 |
Why?
|
| Bone Density Conservation Agents | 3 | 2010 | 795 | 0.560 |
Why?
|
| Dexamethasone | 5 | 2024 | 1944 | 0.550 |
Why?
|
| Treatment Outcome | 54 | 2024 | 64591 | 0.540 |
Why?
|
| Niacinamide | 3 | 2013 | 413 | 0.540 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2015 | 152 | 0.540 |
Why?
|
| Cyclobutanes | 1 | 2016 | 57 | 0.540 |
Why?
|
| Pyridones | 3 | 2021 | 807 | 0.530 |
Why?
|
| Molecular Targeted Therapy | 5 | 2024 | 2805 | 0.530 |
Why?
|
| Urinary Retention | 2 | 2016 | 106 | 0.520 |
Why?
|
| Pericarditis | 3 | 2022 | 134 | 0.510 |
Why?
|
| Skin Neoplasms | 4 | 2023 | 5815 | 0.510 |
Why?
|
| Antineoplastic Agents | 14 | 2022 | 13616 | 0.510 |
Why?
|
| Quinuclidines | 4 | 2022 | 24 | 0.500 |
Why?
|
| Schizophrenia | 9 | 2017 | 6927 | 0.480 |
Why?
|
| Costs and Cost Analysis | 12 | 2019 | 1668 | 0.460 |
Why?
|
| Proton Pump Inhibitors | 2 | 2009 | 530 | 0.450 |
Why?
|
| Body Weight | 4 | 2023 | 4614 | 0.450 |
Why?
|
| Venous Thromboembolism | 7 | 2018 | 1863 | 0.440 |
Why?
|
| Benzenesulfonates | 2 | 2011 | 166 | 0.440 |
Why?
|
| Models, Economic | 5 | 2017 | 716 | 0.440 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 5296 | 0.440 |
Why?
|
| Ambulatory Care | 4 | 2017 | 2771 | 0.440 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2021 | 6471 | 0.440 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 973 | 0.430 |
Why?
|
| Complement Inactivating Agents | 2 | 2023 | 53 | 0.430 |
Why?
|
| Patient Compliance | 5 | 2019 | 2689 | 0.430 |
Why?
|
| Insurance, Physician Services | 1 | 2013 | 23 | 0.430 |
Why?
|
| Heart Failure | 6 | 2022 | 11653 | 0.430 |
Why?
|
| Drug Therapy, Combination | 11 | 2022 | 6297 | 0.430 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 1378 | 0.420 |
Why?
|
| Aged, 80 and over | 36 | 2024 | 58859 | 0.420 |
Why?
|
| Contraception | 1 | 2016 | 348 | 0.420 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 311 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2019 | 12127 | 0.420 |
Why?
|
| Status Epilepticus | 2 | 2019 | 458 | 0.420 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2016 | 487 | 0.420 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2019 | 779 | 0.420 |
Why?
|
| Obesity | 4 | 2023 | 12918 | 0.420 |
Why?
|
| Defibrillators, Implantable | 1 | 2022 | 1488 | 0.410 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2024 | 5662 | 0.410 |
Why?
|
| Young Adult | 36 | 2024 | 59068 | 0.410 |
Why?
|
| Early Diagnosis | 2 | 2014 | 1183 | 0.400 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2019 | 2052 | 0.400 |
Why?
|
| Kidney Failure, Chronic | 5 | 2008 | 2462 | 0.400 |
Why?
|
| Blood Pressure | 5 | 2018 | 8479 | 0.400 |
Why?
|
| Octreotide | 3 | 2019 | 153 | 0.400 |
Why?
|
| Renal Insufficiency | 2 | 2008 | 809 | 0.400 |
Why?
|
| Menorrhagia | 1 | 2012 | 59 | 0.390 |
Why?
|
| Angiomyolipoma | 3 | 2018 | 186 | 0.390 |
Why?
|
| Rotavirus Vaccines | 3 | 2017 | 62 | 0.390 |
Why?
|
| Somatostatin | 5 | 2019 | 447 | 0.390 |
Why?
|
| Immunosuppressive Agents | 3 | 2022 | 4168 | 0.380 |
Why?
|
| Quality Indicators, Health Care | 2 | 2021 | 1792 | 0.380 |
Why?
|
| Health Expenditures | 7 | 2017 | 2353 | 0.380 |
Why?
|
| Triazines | 4 | 2022 | 311 | 0.370 |
Why?
|
| Efficiency | 3 | 2020 | 476 | 0.370 |
Why?
|
| Risperidone | 1 | 2013 | 380 | 0.370 |
Why?
|
| Central Nervous System Stimulants | 1 | 2020 | 1176 | 0.370 |
Why?
|
| Anti-HIV Agents | 2 | 2024 | 4518 | 0.370 |
Why?
|
| Phenylcarbamates | 1 | 2010 | 38 | 0.370 |
Why?
|
| Adolescent | 41 | 2024 | 88196 | 0.370 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2023 | 2163 | 0.370 |
Why?
|
| Hemoglobins | 5 | 2023 | 1524 | 0.360 |
Why?
|
| Epoetin Alfa | 9 | 2009 | 78 | 0.360 |
Why?
|
| Fructose | 2 | 2010 | 288 | 0.360 |
Why?
|
| Lung Neoplasms | 10 | 2023 | 13312 | 0.350 |
Why?
|
| Indans | 1 | 2010 | 92 | 0.350 |
Why?
|
| Hypertension | 5 | 2018 | 8527 | 0.350 |
Why?
|
| Electronic Health Records | 10 | 2024 | 4789 | 0.340 |
Why?
|
| Escherichia coli Infections | 2 | 2024 | 523 | 0.340 |
Why?
|
| Acetaminophen | 2 | 2010 | 554 | 0.330 |
Why?
|
| Administration, Cutaneous | 3 | 2018 | 712 | 0.330 |
Why?
|
| Hand Dermatoses | 2 | 2006 | 62 | 0.320 |
Why?
|
| Neuroendocrine Tumors | 5 | 2019 | 642 | 0.320 |
Why?
|
| Quality of Life | 11 | 2023 | 13338 | 0.320 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 241 | 0.320 |
Why?
|
| Antihypertensive Agents | 3 | 2013 | 2018 | 0.320 |
Why?
|
| Carcinoma, Small Cell | 2 | 2008 | 420 | 0.320 |
Why?
|
| Suicide | 1 | 2020 | 1598 | 0.310 |
Why?
|
| European Union | 1 | 2009 | 157 | 0.310 |
Why?
|
| Bone Neoplasms | 4 | 2020 | 2525 | 0.300 |
Why?
|
| Recurrence | 10 | 2024 | 8466 | 0.300 |
Why?
|
| Severity of Illness Index | 13 | 2022 | 15820 | 0.300 |
Why?
|
| Recombinant Proteins | 12 | 2009 | 6525 | 0.300 |
Why?
|
| Benzoates | 2 | 2020 | 211 | 0.300 |
Why?
|
| Hydrazines | 2 | 2020 | 224 | 0.290 |
Why?
|
| Nitriles | 5 | 2021 | 969 | 0.290 |
Why?
|
| Colorectal Neoplasms | 4 | 2021 | 6894 | 0.290 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2009 | 321 | 0.290 |
Why?
|
| Incidence | 15 | 2024 | 21322 | 0.290 |
Why?
|
| HIV Infections | 3 | 2024 | 17328 | 0.290 |
Why?
|
| Urinary Tract Infections | 2 | 2024 | 806 | 0.280 |
Why?
|
| Erythropoiesis | 2 | 2008 | 682 | 0.280 |
Why?
|
| HIV-1 | 1 | 2024 | 6859 | 0.280 |
Why?
|
| Cost-Benefit Analysis | 7 | 2023 | 5491 | 0.280 |
Why?
|
| Work | 2 | 2020 | 195 | 0.280 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 2204 | 0.280 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2009 | 629 | 0.280 |
Why?
|
| Follow-Up Studies | 19 | 2024 | 39078 | 0.280 |
Why?
|
| Medicare | 8 | 2023 | 6732 | 0.270 |
Why?
|
| Thalassemia | 2 | 2019 | 268 | 0.270 |
Why?
|
| Prospective Payment System | 1 | 2007 | 136 | 0.270 |
Why?
|
| Iron | 1 | 2014 | 1787 | 0.270 |
Why?
|
| Boron Compounds | 2 | 2024 | 182 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 9267 | 0.260 |
Why?
|
| Vaccination | 5 | 2019 | 3375 | 0.260 |
Why?
|
| Bone Diseases | 1 | 2010 | 419 | 0.260 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 891 | 0.260 |
Why?
|
| Androstadienes | 3 | 2022 | 348 | 0.260 |
Why?
|
| Pyridazines | 2 | 2018 | 201 | 0.260 |
Why?
|
| Renal Dialysis | 4 | 2008 | 1795 | 0.260 |
Why?
|
| Azithromycin | 2 | 2022 | 199 | 0.250 |
Why?
|
| Algorithms | 6 | 2024 | 14002 | 0.250 |
Why?
|
| Body Mass Index | 3 | 2019 | 12932 | 0.250 |
Why?
|
| International Classification of Diseases | 4 | 2022 | 892 | 0.250 |
Why?
|
| Medical Records | 6 | 2019 | 1407 | 0.240 |
Why?
|
| Estrogens | 3 | 2018 | 1519 | 0.240 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 3702 | 0.230 |
Why?
|
| Gastroesophageal Reflux | 2 | 2009 | 816 | 0.230 |
Why?
|
| Pregnancy, Unplanned | 2 | 2016 | 85 | 0.230 |
Why?
|
| Multivariate Analysis | 15 | 2019 | 12054 | 0.230 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 410 | 0.230 |
Why?
|
| Neutropenia | 1 | 2009 | 884 | 0.230 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 4849 | 0.230 |
Why?
|
| Sick Leave | 2 | 2020 | 105 | 0.230 |
Why?
|
| Glycine | 2 | 2024 | 665 | 0.230 |
Why?
|
| Kidney Diseases | 3 | 2010 | 2093 | 0.230 |
Why?
|
| Dermatitis | 1 | 2006 | 200 | 0.230 |
Why?
|
| Mutation | 5 | 2024 | 30025 | 0.230 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2007 | 385 | 0.230 |
Why?
|
| Neoplasm Metastasis | 6 | 2024 | 4903 | 0.220 |
Why?
|
| Europe | 4 | 2023 | 3419 | 0.220 |
Why?
|
| Proportional Hazards Models | 8 | 2022 | 12429 | 0.220 |
Why?
|
| SEER Program | 3 | 2019 | 1449 | 0.220 |
Why?
|
| Health Maintenance Organizations | 1 | 2006 | 660 | 0.220 |
Why?
|
| Polypharmacy | 2 | 2020 | 305 | 0.220 |
Why?
|
| Eosinophils | 2 | 2018 | 947 | 0.220 |
Why?
|
| Immunotherapy | 1 | 2019 | 4649 | 0.220 |
Why?
|
| Pain | 3 | 2023 | 5075 | 0.220 |
Why?
|
| Lung | 2 | 2019 | 9973 | 0.210 |
Why?
|
| Complement C5 | 1 | 2023 | 106 | 0.210 |
Why?
|
| Risk Factors | 19 | 2024 | 74055 | 0.210 |
Why?
|
| Androgen Antagonists | 2 | 2024 | 1407 | 0.210 |
Why?
|
| Cardiovascular Diseases | 7 | 2024 | 15476 | 0.210 |
Why?
|
| Androstenes | 3 | 2021 | 181 | 0.210 |
Why?
|
| Phenylthiohydantoin | 3 | 2021 | 205 | 0.210 |
Why?
|
| Cancer Care Facilities | 4 | 2021 | 422 | 0.200 |
Why?
|
| Age Factors | 7 | 2020 | 18379 | 0.200 |
Why?
|
| Iron Overload | 2 | 2018 | 239 | 0.200 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2022 | 33 | 0.200 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2023 | 97 | 0.200 |
Why?
|
| Carcinoid Tumor | 2 | 2019 | 224 | 0.200 |
Why?
|
| Piperidines | 1 | 2010 | 1656 | 0.200 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 170 | 0.200 |
Why?
|
| Vaccines, Attenuated | 3 | 2017 | 314 | 0.190 |
Why?
|
| Taxoids | 3 | 2024 | 666 | 0.190 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2023 | 212 | 0.190 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2022 | 122 | 0.190 |
Why?
|
| Comorbidity | 12 | 2021 | 10494 | 0.180 |
Why?
|
| Pyrazoles | 3 | 2022 | 2007 | 0.180 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 102 | 0.180 |
Why?
|
| Child | 23 | 2022 | 80086 | 0.180 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2018 | 1208 | 0.180 |
Why?
|
| Emergency Service, Hospital | 6 | 2015 | 7860 | 0.180 |
Why?
|
| Disability Evaluation | 1 | 2008 | 1834 | 0.180 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2012 | 357 | 0.180 |
Why?
|
| Peptides, Cyclic | 2 | 2019 | 392 | 0.180 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2018 | 38 | 0.180 |
Why?
|
| Paris | 1 | 2020 | 42 | 0.180 |
Why?
|
| Quebec | 2 | 2012 | 140 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 1010 | 0.170 |
Why?
|
| Radium | 1 | 2020 | 72 | 0.170 |
Why?
|
| Accidental Falls | 1 | 2008 | 1066 | 0.170 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 1371 | 0.170 |
Why?
|
| Republic of Korea | 1 | 2021 | 571 | 0.170 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 2946 | 0.170 |
Why?
|
| Erythrocyte Transfusion | 4 | 2015 | 565 | 0.170 |
Why?
|
| Carcinoma | 1 | 2011 | 2328 | 0.170 |
Why?
|
|